An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER-2 study design
Faruk Ertas, Hasan Kaya, Abdulkadir Yildiz, Murat Yuksel, Halit Acet, Habib Cil, Sait Alan, Nizamettin Toprak, Vedat Davutoglu, Abdulkadir Kiris, Lale Dinc, Habibe Kafes, Anil Avci, Bekir Calapkorur, Gokhan Ertas, Mehmet Gul, Nuray Kahraman Ay, Serkan Bulur, Mine Durukan, Murat Eren, Ibrahim Ilhan, Murathan Kucuk, Ebru Ozpelit, Hakki Simsek, F. Mehmet Ucar, Ahmet Yildiz, D. Yildiray Sahin, Erkan Ayhan, C. Emre Caglayan, Hasan Gungor, Ferhat Ozyurtlu, Nihat Sen, Bulent Vatan, Fahriye Vatansever, Mehmet Ali Kobat, Ahmet Temiz, Gokay Taylan, Ibrahim Donmez, M. Emre Erkus, Selami Soylemez, Halit Zengin, Mahmut Gunduz, Abdullah Tuncez, Yusuf Karavelioglu, Tayyar Gokdeniz, Yavuzer Koza, Z. Aktop, Huseyin Katlandur, Pelin Karaca Ozer
article (Uluslararası, Hakemli) | Yazar(lar): Faruk Ertas, Hasan Kaya, Abdulkadir Yildiz, Murat Yuksel, Halit Acet, Habib Cil, Sait Alan, Nizamettin Toprak, Vedat Davutoglu, Abdulkadir Kiris, Lale Dinc, Habibe Kafes, Anil Avci, Bekir Calapkorur, Gokhan Ertas, Mehmet Gul, Nuray Kahraman Ay, Serkan Bulur, Mine Durukan, M
Objectives: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke and is related to increased cardiovascular morbidity and mortality. There is a lack of data in Turkey on the use of new oral anticoagulants (NOACs), and time in therapeutic INR range (TTR) in vitamin K antagonist users and AF management modality. In this multi-center trial, we aimed to analyze, follow and evaluate the epidemiological data in non-valvular AF patients.
Study design: Four thousand one hundred consecutive adult patients from 42 centers with at least one AF attack identified on electrocardiography will be included in the study. Patients with rheumatic mitral valve stenosis and prosthetic valve disease will be excluded from the study. At the end of one year, the patients will be evaluated in terms of major cardiac end points (death, transient ischemic attack, stroke, systemic thromboembolism, major bleeding and hospitalization).
Results: First results are expected in June 2015. Data about major cardiovascular end-points will be available in January 2016.
Conclusion: The rates and kind of oral anticoagulant use, TTR in vitamin K antagonist users and main management modality applied in non-valvular AF patients will be determined by AFTER-2 study. In addition, the rate of major adverse events (MACEs) and the independent predictors of these MACEs will be detected (AFTER-2 Study ClinicalTrials. gov number, NCT02354456.).